Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Net Margin (2016 - 2025)

Historic Net Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 27.14%.

  • Adma Biologics' Net Margin fell 28200.0% to 27.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.87%, marking a year-over-year increase of 250700.0%. This contributed to the annual value of 46.35% for FY2024, which is 572900.0% up from last year.
  • Latest data reveals that Adma Biologics reported Net Margin of 27.14% as of Q3 2025, which was down 28200.0% from 28.05% recorded in Q2 2025.
  • Adma Biologics' 5-year Net Margin high stood at 95.19% for Q4 2024, and its period low was 114.26% during Q1 2021.
  • Its 5-year average for Net Margin is 13.94%, with a median of 11.93% in 2023.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 1534600bps in 2021, then tumbled by -28200bps in 2025.
  • Adma Biologics' Net Margin (Quarter) stood at 30.01% in 2021, then increased by 21bps to 23.59% in 2022, then decreased by -1bps to 23.88% in 2023, then skyrocketed by 499bps to 95.19% in 2024, then plummeted by -71bps to 27.14% in 2025.
  • Its last three reported values are 27.14% in Q3 2025, 28.05% for Q2 2025, and 23.44% during Q1 2025.